BRIDGEWATER, N.J., May 28, 2024 /PRNewswire/ Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today
Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
-Phase 3 Study Achieves Primary Endpoint for Both Dosage Strengths of Brensocatib with Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus
BRIDGEWATER, N.J., May 28, 2024 /PRNewswire/ Insmed Incorporated , a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today.
The global opioid use disorder treatment market size is expected to attain an impressive valuation of US$ 3.07 billion in 2023 and is projected to reach US$ 8.4 billion by 2033, expanding at a CAGR of 10.5% during the forecast period. The drug abuse treatment providers and manufacturers primarily focus on creating a.